Skip to content

Effect of intra-articular Triamcinolone and combined Ketorolac-Triamcinolone injection in treatment of patient with primary osteoarthritis; A Randomized controlled trial

Effect of intra-articular Triamcinolone and combined Ketorolac-Triamcinolone injection in treatment of patient with primary osteoarthritis; A Randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210728004
Enrollment
80
Registered
2021-07-28
Start date
2021-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary osteoarthritis Primary osteoarthritis Ketorolac tromethamine Triamcinolone acetonide

Interventions

Knee intraarticular injection with triamcinolone acetonide (40mg/1mL) 1 mL + 1% Lidocaine 3 mL ,Knee intraarticular injection with triamcinolone acetonide (40mg/1mL) 1 mL + 1% Lidocaine 3 mL + Ketorol
Active Comparator Drug,Active Comparator Drug
Group1 ,Group2

Sponsors

Faculty of medicine, prince of songkla university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to No maximum

Inclusion criteria

Inclusion criteria: 1 Age older than 45 years old 2 Patient who was diagnosed as primary osteoarthritis by ACR criteria with knee pain more than 3 months 3 Patient who were radiologically classified in Kellgren and Lawrence classification 2 or 3 4 VAS more than 4

Exclusion criteria

Exclusion criteria: 1 History of knee replacement or open knee surgery 2 Previous arthroscopic knee procedure within 6 months prior 3 Previous intraarticular injection within 3 months prior 4 Allergy of NSAIDs Corticosteroid and Lidocaine 5 Currently usage of anticoagulants corticosteroid and indomethacin 6 Patient with severely impaired cognitive function which is unable to evaluate outcomes and follow research protocol 7 Patient with severely illness such as poor controlled diabetes mellitus HbA1C more than 7.5% 8 Significant chronic kidney disease; GFR < 60 mL/minute within past 1 month 9 Patient who is currently or recently participating in any clinical trial

Design outcomes

Primary

MeasureTime frame
Pain score at 1 and 3 month Visual analog scale

Secondary

MeasureTime frame
Functional score at 1, 3 and 6 months KOOS score ,Pain score at 6 months Visual analog scale,Adverse effect at 1,3 and 6 months Questionnaire

Countries

Thailand

Contacts

Public ContactKhanin Iamthanaporn

Prince of Songkla University

Khanin.i@psu.ac.th0815558362

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026